Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2020, Vol. 52 ›› Issue (1): 152-157. doi: 10.19723/j.issn.1671-167X.2020.01.024

Previous Articles     Next Articles

Protective effect of cardiopulmonary fitness on patients with high risk of atherosclerotic cardiovascular disease

Chuan REN1,Xiao-yue WU1,Wei ZHAO1,2,△(),Li-yuan TAO3,Ping LIU1,Wei GAO1   

  1. 1. Department of Cardiology, Peking University Third Hospital; Institute of Vascular Medicine of Peking University Third Hospital; Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of National Health Commission; Key Laboratory of Molecular Cardiovascular Science of Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China
    2. Physical Examination Center, Peking University Third Hospital, Beijing 100191, China
    3. Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China
  • Received:2019-09-24 Online:2020-02-18 Published:2020-02-20
  • Contact: Wei ZHAO E-mail:beate_vv@ bjmu.edu.cn
  • Supported by:
    Supported by the CS Optimizing Antithrombotic Research Fund(BJUHFCSOARF201801-11);Capital Clinical Application Research and Promotion Projects of Beijing Municipal Science and Technology Commission(Z151100004015047);National Natural Science Foundation of China(81601968)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To evaluate the effects of cardiopulmonary fitness on arteriosclerotic cardiovascular disease (ASCVD) events in patients with different risks of ASCVD. Methods: This study enrolled 544 non ASCVD patients who underwent cardiopulmonary exercise testing in Peking University Third Hospital from September 2016 to April 2018. ASCVD overall risk assessment was conducted according to “Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia”. Peak oxygen uptake (VO2peak), the classic indicator of cardiopulmonary fitness, was accurately determined by cardiopulmonary exercise testing in all the patients. All of the patients were followed up clinically. Results: In the study, 506 patients completed the follow-up (250 low-risk patients, 93 moderate-risk patients and 163 high-risk patients). The median follow-up period was 19 months (9-28 months), and 51 patients developed ASCVD events during the follow-up period, of whom, 33 cases developed myocardial infarction, unstable angina or coronary revascularization, and 18 cases ischemic stroke, transient ischemic attack or carotid vascular revascularization. The patients were divided into the ASCVD group (n=51) and the non ASCVD group (n=455) based on the presence or absence of ASCVD events. VO2peak [16.3(3.6) mL(kg·min) vs. 19.1(3.2) mL/(kg·min), P<0.001] in the ASCVD group were significantly lower than that in the non ASCVD group. Logistic regression analysis found VO2peak [OR 0.893 (95%CI:0.831-0.959), P=0.002] and ASCVD risk stratification [OR 1.428 (95%CI:1.028-1.878), P=0.031] were both independently associated with the occurrence of ASCVD events, which meant that every 1 mL/(kg·min) of increase in VO2peak, the risk of ASCVD events was reduced by 11%. The patients were divided into low, moderate, and high VO2peak according to the tertiles of their VO2peak [14.4 mL/(kg·min), and 23.0 mL/(kg·min)]. Logistic regression analyses were performed using ASCVD events as a dependent variable in the patients with high-risk and low/moderate-risk of ASCVD respectively. In the patients with high-risk of ASCVD, the results suggested that the incidence of ASCVD events was significantly decreased in the patients with moderate VO2 peak [OR 0.210 (95%CI:0.054-0.814), P=0.024] and high VO2 peak [OR 0.146 (95%CI:0.025-0.870), P=0.035], but no significant effect of VO2 peak elevation on the incidence of ASCVD events was found in the low/moderate-risk ASCVD patients. Conclusion: High cardiopulmonary fitness can significantly reduce the occurrence of ASCVD events in patients with high-risk of ASCVD.

Key words: Arteriosclerotic cardiovascular disease, Risk stratification, Cardiopulmonary exercise testing, Cardiorespiratory fitness

CLC Number: 

  • R541.4

Table 1

General information of ASCVD group and non ASCVD group"

Items Non ASCVD group(n=455) ASCVD group(n=51) P
Age/years, x?±s 56.0±13.1 63.7±9.2 <0.001
Gender 0.084
Male, n(%) 224(49.2) 32(62.7)
Female, n (%) 231(50.8) 19(37.3)
BMI/(kg/m2), x?±s 25.3±3.8 26.2±3.0 0.105
Medical History
Hypertension, n (%) 189(41.5) 30(58.8) 0.023
Hyperlipidemia, n (%) 196(43.1) 25(49.0) 0.473
Diabetes, n (%) 82(18.0) 13(25.5) 0.215
Smoking, n (%) 118(25.9) 17(33.3) 0.287
Laboratory tests
TC/(mmol/L), x?±s 4.71±0.97 4.43±1.18 0.058
LDL-C/(mmol/L), M(IQR) 1.88(1.01) 2.13(0.71) 0.616
HDL-C/(mmol/L), M(IQR) 1.16(0.20) 1.05(0.22) 0.011
TG/(mmol/L), x?±s 2.53±1.02 2.31±1.04 0.163
FBG/(mmol/L), M(IQR) 5.5(0.7) 5.7(0.8) 0.805
HbAlc, n (%) 5.9(0.6) 6.1(0.8) 0.433
Medication
ACEI/ARB, n (%) 73(16.0) 13(25.4) 0.204
β-blockers, n (%) 54(11.9) 8(15.7) 0.456
Calcium channel blockers, n (%) 82(18.0) 16(31.4) 0.026
Statins, n (%) 103(22.6) 23(45.1) 0.001
Aspirin, n (%) 60(13.2) 19(37.3) <0.001
Cardiopulmonary exercise testing
VO2peak/[mL/(kg·min)], M(ITR) 19.1(3.2) 16.3(3.6) <0.001
Positive result, n (%) 30(6.6) 4(7.8) 0.189

Table 2

General information of ASCVD group and non ASCVD group in ASCVD low /moderate risk and high risk populations"

Items Low /moderate risk High risk
Non ASCVD group
(n=313)		 ASCVD group
(n=30)		 P Non ASCVD group
(n=142)		 ASCVD group
(n=21)		 P
Age/years, x?±s 55.3±13.6 65.1±9.1 <0.001 57.6±11.6 61.8±9.2 0.117
Gender 0.152 0.479
Male, n(%) 145(46.3) 18(60.0) 79(55.6) 14(66.7)
Female, n (%) 168(53.7) 12(40.0) 63(44.4) 7(33.3)
BMI, kg/m2 24.8±3.5 26.2±2.8 0.039 26.6±4.0 26.3±3.4 0.740
Medical History
Hypertension, n (%) 93(29.7) 14(46.7) 0.056 96(67.7) 16(76.2) 0.630
Hyperlipidemia, n (%) 121(38.6) 12(40.0) 0.885 75(52.8) 13(61.9) 0.585
Diabetes, n (%) 6(1.9) 2(6.7) 0.100 76(53.5) 11(52.4) 0.737
Smoking, n (%) 60(19.2) 8(26.7) 0.325 58(40.8) 9(42.9) 0.993
Laboratory tests
TC/(mmol/L), x?±s 4.66±0.90 4.16±1.04 0.005 4.84±1.09 4.83±1.29 0.957
LDL-C/(mmol/L), M(IQR) 1.75(1.02) 1.74(1.22) 0.637 2.26(0.77) 2.46(0.74) 0.186
HDL-C/(mmol/L), M(IQR) 1.20(0.19) 1.11(0.20) 0.084 1.02(0.20) 0.90(0.33) 0.326
TG/(mmol/L), x?±s 2.41±0.97 2.06±0.80 0.052 2.80±1.07 2.66±1.24 0.588
FBG/(mmol/L), M(IQR) 5.4(0.5) 5.6(0.3) 0.735 6.4(1.6) 6.2(1.6) 0.341
HbAlc, n (%) 5.7(0.3) 5.7(0.5) 0.575 6.5(1.5) 6.6(1.3) 0.961
Medication
ACEI/ARB, n (%) 41(13.1) 5(16.7) 0.584 32(22.5) 8(38.1) 0.122
β-blockers, n (%) 32(10.2) 3(10.0) 0.969 22(15.5) 5(23.8) 0.397
Calcium channel blockers, n (%) 45(14.4) 9(30.0) 0.025 37(26.1) 7(33.3) 0.575
Statins, n (%) 70(22.3) 14(46.7) 0.004 33(23.2) 9(42.9) 0.052
Aspirin, n (%) 43(13.7) 10(33.3) 0.005 17(12.0) 9(42.9) 0.001
Cardiopulmonary exercise testing
VO2peak, mL/(kg·min), M(ITR) 19.4(3.1) 16.1(4.4) 0.006 18.8(2.8) 16.3(1.7) 0.014
Positive result, n (%) 16(5.1) 2(6.7) 0.340 14(9.9) 2(9.5) 0.242

Figure 1

Logistic regression analysis of ASCVD events by categories of VO2peak in ASCVD low /moderate risk and high risk populations Model is adjusted for age, gender, BMI, TC, calcium channel blockers use, statin use, aspirin use. VO2peak, peak oxygen uptake; ASCVD, arteriosclerotic cardiovascular disease; BMI, body mass index; TC, total cholesterol; OR, odds ratio."

[1] Ross R, Blair SN, Arena R , et al. Importance of assessing cardiorespiratory fitness in clinical practice: A case for fitness as a clinical vital sign: A scientific statement from the American Heart Association[J]. Circulation, 2016,134(24):e653-e699.
[2] Hannan AL, Hing W, Simas V , et al. High-intensity interval training versus moderate-intensity continuous training within cardiac rehabilitation: A systematic review and meta-analysis[J]. Open Access J Sports Med, 2018,9:1-17.
[3] Letnes JM, Dalen H, Vesterbekkmo EK , et al. Peak oxygen uptake and incident coronary heart disease in a healthy population: the HUNT fitness study[J]. Eur Heart J, 2019,40(20):1633-1639.
[4] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016,31(10):937-951.
[5] Skalski J, Allison TG, Miller TD , et al. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases[J]. Circulation, 2012,126(21):2465-2472.
[6] Stamatakis E, Hamer M, O'Donovan G , et al. A non-exercise testing method for estimating cardiorespiratory fitness: Associations with all-cause and cardiovascular mortality in a pooled analysis of eight population-based cohorts[J]. Eur Heart J, 2013,34(10):750-758.
[7] Gander J, Lee DC, Sui X , et al. Self-rated health status and cardiorespiratory fitness as predictors of mortality in men[J]. Br J Sports Med, 2011,45(14):1095-1100.
[8] Kim D, Park W . The inverse relationship between cardiorespiratory fitness and intima- media thickness with prehypertensive middle-aged woman[J]. Tohoku J Exp Med, 2017,243(4):283-288.
[9] Brawner CA, Al-Mallah MH, Ehrman JK , et al. Change in maximal exercise capacity is associated with survival in men and women[J]. Mayo Clin Proc, 2017,92(3):383-390.
[10] Ehrman JK, Brawner CA, Al-Mallah MH , et al. Cardiorespiratory fitness change and mortality risk among black and white patients: Henry Ford Exercise Testing (FIT) project[J]. Am J Med, 2017,130(10):1177-1183.
[11] Kelley E, Imboden MT, Harber MP , et al. Cardiorespiratory fitness is inversely associated with clustering of metabolic syndrome risk factors: The ball state adult fitness program longitudinal life-style study[J]. Mayo Clin Proc Innov Qual Outcomes, 2018,2(2):155-164.
[12] Mora S, Redberg RF, Cui Y , et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: A 20-year follow-up of the lipid research clinics prevalence study[J]. JAMA, 2003,290(12):1600-1607.
[13] Barker AR, Gracia-Marco L, Ruiz JR , et al. Physical activity, sedentary time, TV viewing, physical fitness and cardiovascular disease risk in adolescents: The HELENA study[J]. Int J Car-diol, 2018,254:303-309.
[14] Williams PT . Physical fitness and activity as separate heart disease risk factors: A meta-analysis[J]. Med Sci Sports Exerc, 2001,33(5):754-761.
[15] Ekblom-Bak E, Hellénius ML, Ekblom O , et al. Independent associations of physical activity and cardiovascular fitness with cardiovascular risk in adults[J]. Eur J Cardiovasc Prev Rehabil, 2010,17(2):175-180.
[16] Pinkstaff S, Peberdy MA, Kontos MC , et al. Overestimation of aerobic capacity with the bruce treadmill protocol in patients being assessed for suspected myocardial ischemia[J]. J Cardiopulm Rehabil Prev, 2011,31(4):254-260.
[1] Qi MIAO, Baoan HONG, Xuezhou ZHANG, Zhipeng SUN, Wei WANG, Yuxuan WANG, Yuxuan BO, Jiahui ZHAO, Ning ZHANG. Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 698-703.
[2] Huan LIU,Ying-dong HE,Jin-bo LIU,Wei HUANG,Na ZHAO,Hong-wei ZHAO,Xiao-hua ZHOU,Hong-yu WANG. Predictive value of vascular health indicators on newly cardiovascular events: Preliminary validation of Beijing vascular health stratification system [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 514-520.
[3] Wen-qiang SUN,Zhou ZHAO,Qing GAO,Zeng-qiang HAN,Wei YANG,Bo LIAN,Gang LIU,Sheng-long CHEN,Yu CHEN. Effects of intraoperative graft flow measurements on the early mid-term outcomes after off-pump coronary artery bypass grafting [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 851-855.
[4] Jing ZHANG,Su-fang LI,Hong CHEN,Jun-xian SONG. Role of miR-106b-5p in the regulation of gene profiles in endothelial cells [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 221-227.
[5] LIU Teng-fei, ZHANG Jing-wei, CHEN Xia-huan, FENG Xue-ru, BAI Zhong-sheng, LIU Mei-lin. Association between CMTM5 gene rs723840 single nucleotide polymorphism and high on asprin platelet reactivity [J]. Journal of Peking University(Health Sciences), 2015, 47(6): 905-909.
[6] LIU Teng-fei, ZHANG Jing-wei, CHEN Xia-huan, FENG Xue-ru, BAI Zhong-sheng, LIU Mei-lin. Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabete and coronary artery disease [J]. Journal of Peking University(Health Sciences), 2015, 47(6): 920-924.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd